Clinical trials: Bird Flu
Influenza, Avian Influenza
Safety Trial of Live Attenuated Influenza (H7N3) Vaccine
The study hypothesis is that two doses of cold-adapted, live monovalent A/17/mallard/Netherlands/00/95 (H7N3) influenza vaccine will be safe and immunogenic in healthy adults.
- Trial name
- NCT01511419
- Testing
- LAIV H7N3
- Where
- Russia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- PATH
H7N9 Influenza
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
- Trial name
- NCT01928472
- Testing
- H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant
- Where
- 6 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A Subtype H5N1 Infection
Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1
This is a first-in-human study of safety and immunogenicity of an A/H5N1 inactivated whole cell vaccine when given in two injections in two doses (low and high) compared to a placebo in 76 healthy adult subjects in Vietnam.
- Trial name
- NCT02171819
- Testing
- IVACFLU-A/H5N1, 7.5 mcg, IVACFLU-A/H5N1, 15 mcg
- Where
- Vietnam
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Avian Influenza, Influenza Immunisation
2017 A/H7N9 IIV Revaccination
This is a Phase II clinical trial in up to 420 males and non-pregnant females, 19 to 70 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03738241
- Testing
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Where
- 9 sites in United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Influenza Vaccines
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
- Trial name
- NCT01788228
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
This study may provide safety information on a flu vaccine given to children and may provide immunogenicity information to add to what was collected in a previous flu vaccine study.
- Trial name
- NCT00402649
- Testing
- Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Subtype H5N1 Infection
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the…
- Trial name
- HIPCVAX-010S (NCT03701061)
- Testing
- Seasonal Influenza Vaccine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Emory University
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
- Trial name
- NCT00771615
- Testing
- GSK A/turkey H5N1 Influenza vaccine
- Where
- 10 sites in United States, Canada
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Influenza Vaccines
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to < 18 years of age.
- Trial name
- NCT01310413
- Testing
- Influenza A (H5N1) Virus monovalent vaccine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza Disease
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
The present study, phase III, randomized, controlled, observer-blind, multicenter study, will evaluate safety, tolerability and immunogenicity of two doses of an adjuvanted monovalent influenza vaccine compared with an adjuvanted…
- Trial name
- NCT00841763
- Testing
- Trivalent influenza virus vaccine (TIV), Adjuvanted monovalent influenza virus vaccine (aH5N1), Adjuvanted trivalent influenza virus vaccine (aTIV)
- Where
- 2 sites in Finland, Germany
- Volunteers
- 3,647 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Vaccine
Immunogenicity of H5N1 Vaccine Following H5N2
This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can induce a long-lasting immune memory by comparing the immunologic response to two doses of the OrniFlu® inactivated vaccine given to subjects…
- Trial name
- NCT02153671
- Testing
- A(H5N1) inactivated influenza vaccine (IIV), A(H5N2) live attenuated influenza vaccine (LAIV)
- Where
- Russia
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A Virus, H5N1 Subtype
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
This study will compare the different immune responses to Influenza A (H5N1) Virus Monovalent Vaccine with and without the AS03 adjuvant.
- Trial name
- NCT01910519
- Testing
- H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
- Trial name
- NCT04789577
- Testing
- FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3
- Where
- 8 sites in United States
- Volunteers
- 833 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Avian Influenza, Influenza Immunisation
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females, 18-64 years of age. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a pre-pandemic 2017…
- Trial name
- NCT03682120
- Testing
- A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent
- Where
- 7 sites in United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A Virus, H5N1 Subtype
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to…
- Trial name
- NCT03497845
- Testing
- VN, IN, dk/BANG
- Where
- 6 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
- Trial name
- NCT01766921
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 1,393 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines